Bayer (ETR:BAYN) Rating Kept
They currently have a EUR 137.50 TP on Bayer (ETR:BAYN). Warburg Research’s target would suggest a potential upside of 22.88% from the company’s previous close. This was revealed to investors in an analyst report on Friday, 23 October.
ETR:BAYN is at the moment trading 0.00% lower at EUR 111.65 as of 09:25 Frankfurt time. Bayer’s stock is down -5.8% in the past 200 days. It has underperformed the S&P 500 Index, which has surged 1.31% in the same time.
According to data compiled by Thomson Reuters, Bayer (ETR:BAYN)’s stock is covered by 26 equity analysts across the Street, with 2 analysts giving it a Sell rating, 15 a Buy rating, while 12 consider it a Hold. The 12-month consensus target price for the stock is EUR 139.83, which reflects an upside potential of 25.24% over the current price.
ETR:BAYN Price Chart & Trend
The stock price of Bayer declined 5.8% over the last 200 days, and is in weak down trend. In the last 50 and 100 days, Bayer is down 13.78% and down 13.35%, respectively. Our stocks momentum model is shown on the price chart below.
Bayer (ETR:BAYN) Profile
Bayer AG is a strategic management holding company. The Company’s business operations are organized into three subgroups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare researches, develops, manufactures and markets products to improve the health of people and animals.
Bayer (ETR:BAYN) closed at EUR 111.65 yesterday. A total of shares of the company’s stock traded hands. This is down from average of 2.32 million shares. Bayer has a 52 week low of EUR 103.35 and a 52 week high of EUR 146.45. The company has a market cap of 90.80B EUR and a P/E ratio of 26.47.
Get the latest Bayer (ETR:BAYN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
Bayer - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.